Title:Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem
Volume: 17
Issue: 2
Author(s): Suresh J. Antony*Leigh G. Cooper
Affiliation:
- 1205 N. Oregon, El Paso, Texas 79902,United States
Keywords:
Oritavancin, prosthetic joint, intravenous, lipoglycopeptide, Morbidity, lipoglycopeptide.
Abstract: Prosthetic joint infections (PJI) result in significant morbidity, mortality
and cost to patients and the health system. Traditional treatment involves a twostaged
revision and occasionally a single staged revision along with intravenous antibiotics
(IV) and or oral antibiotics for several weeks to months. The use of a single
staged revision along with an antibiotic which has a prolonged half life and is bactericidal
would be ideal. We present 2 patients who were treated successfully with a
single stage revision/antibiotic spacer and a new novel long acting lipoglycopeptide
called oritavancin.
